U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H19ClN2O3
Molecular Weight 370.829
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIVOXAZEPAM

SMILES

CC(C)(C)C(=O)OC1N=C(C2=CC=CC=C2)C3=C(NC1=O)C=CC(Cl)=C3

InChI

InChIKey=FTJLKTBLZOULCL-UHFFFAOYSA-N
InChI=1S/C20H19ClN2O3/c1-20(2,3)19(25)26-18-17(24)22-15-10-9-13(21)11-14(15)16(23-18)12-7-5-4-6-8-12/h4-11,18H,1-3H3,(H,22,24)

HIDE SMILES / InChI

Molecular Formula C20H19ClN2O3
Molecular Weight 370.829
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Oxazepam is the first of a chemical series of compounds, the 3-hydroxybenzodiazepinones. A therapeutic agent providing versatility and flexibility in control of common emotional disturbances, this product exerts prompt action in a wide variety of disorders associated with anxiety, tension, agitation and irritability, and anxiety associated with depression. Oxazepam has distinguished itself clinically from other benzodiazepines by virtue of its excellent tolerance. Because of its excellent tolerance, dosage is very flexible, and it is, therefore, possible to utilize oxazepam in a wide spectrum of anxiety-related disorders including the psychoses. Oxazepam has been administered to humans by the oral route only. Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg. Age and liver disease have a minimal influence on oxazepam kinetics, but renal disease is associated with a prolonged half-life and increased volume of distribution.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.5 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
OXAZEPAM
Primary
OXAZEPAM

Cmax

ValueDoseCo-administeredAnalytePopulation
268 ng/mL
15 mg single, oral
OXAZEPAM plasma
Homo sapiens
288 ng/mL
10 mg 3 times / day multiple, oral
OXAZEPAM plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
4737 ng × h/mL
10 mg 3 times / day multiple, oral
OXAZEPAM plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
5.7 h
15 mg single, oral
OXAZEPAM plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
5.1%
15 mg single, oral
OXAZEPAM plasma
Homo sapiens
2%
10 mg 3 times / day multiple, oral
OXAZEPAM plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Sample Use Guides

In Vivo Use Guide
Mild-to-moderate anxiety: 10 to 15 mg, 3 or 4 times daily. Severe anxiety syndromes and Alcoholics with acute inebriation, tremulousness, or anxiety on withdrawal: 15 to 30 mg, 3 or 4 times daily. Older patients with anxiety, tension, irritability and agitation: 10 mg, 3 times daily (initial dosage), if necessary, increase cautiously to 15 mg, 3 or 4 times daily.
Route of Administration: Oral
In Vitro Use Guide
On the stretch-induced discharge activity of the isolated crayfish sensory neuron oxazepam only produced depression (less than or equal to 0.5 mM).
Substance Class Chemical
Record UNII
F4ER8Z6Q3U
Record Status Validated (UNII)
Record Version